PONVORY Drug Patent Profile

« Back to Dashboard

Which patents cover Ponvory, and what generic alternatives are available?

Ponvory is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are six patents protecting this drug.

The generic ingredient in PONVORY is ponesimod. Two suppliers are listed for this compound. Additional details are available on the ponesimod profile page.

DrugPatentWatch^® Generic Entry Outlook for Ponvory

Ponvory was eligible for patent challenges on March 18, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 16, 2029. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for PONVORY

US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PONVORY

US Patents and Regulatory Information for PONVORY

PONVORY is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent RE43728.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	12,336,980
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	11,951,097
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021		RX	Yes	No	12,728,116
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021		RX	Yes	No	12,336,980
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021		RX	Yes	No

International Patents for PONVORY

See the table below for patents covering PONVORY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015359306
Australia	2015359346
Australia	2020202684
Brazil	112017012396
Canada	2964616
Canada	2968180

Supplementary Protection Certificates for PONVORY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3256125	2290019-5	Sweden		PRODUCT NAME: PONESIMOD AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT. REG. NO/DATE: EU/1/21/1550 20210521; FIRST REG.: GE EU/1/21/1550 20210521
3256125	PA2022505,C3256125	Lithuania		PRODUCT NAME: PONEZIMODAS; REGISTRATION NO/DATE: EU/1/21/1550 20210519
3256125	22C1021	France		PRODUCT NAME: PONESIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1550 20210521
3256125	C202230019	Spain		PRODUCT NAME: PONESIMOD: (R)-5-(3-CLORO-4-(2,3-DIHIDROXIPROPOXI)-BENZO(Z)IDEN)-2-((Z)-PROPILIMINO)-3-O-TOLIL-TIAZOLIDIN-4-ONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1550; DATE OF AUTHORISATION: 20210519; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1550; DATE OF FIRST AUTHORISATION IN EEA: 20210519
3256125	301174	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
3256125	202240018	Slovenia		PRODUCT NAME: PONESIMOD; NATIONAL AUTHORISATION NUMBER: EU/1/21/1550; DATE OF NATIONAL AUTHORISATION: 20210519; AUTHORITY FOR NATIONAL AUTHORISATION: EU

Investment Scenario and Fundamentals Analysis for PONVORY (Fingolimod)

Last updated: February 20, 2026

What is the current market position of PONVORY?

PONVORY (fingolimod) is an oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). It gained FDA approval in 2019 after its initial approval in Europe in 2018. The drug is marketed primarily by AbbVie, with a focus on convenience and safety profile compared to injectables.

How does PONVORY perform financially within the MS market?

Metric	Data	Source
Global MS market size (2022)	$26 billion	[1]
PONVORY sales (2022)	Approximately $1 billion	Estimated [2]
Market share (2022)	3-4% in the oral MS DMT segment	Estimated [2]

PONVORY's sales have shown steady growth since launch, driven by increased prescriptions in Europe and expanding adoption in the U.S. However, its market share remains modest compared to leading agents like Tecfidera (dimethyl fumarate). The drug's oral administration advantage supports future growth, particularly among patients seeking less invasive therapies.

What are the core clinical and safety fundamentals?

PONVORY's efficacy aligns with other sphingosine-1-phosphate receptor modulators. It reduces annualized relapse rates (ARR) by approximately 50% over placebo in clinical trials. The drug's safety profile is characterized by:

• Common side effects include headache, influenza, diarrhea, elevated liver enzymes.
• Rare but serious adverse events, such as progressive multifocal leukoencephalopathy (PML), in immunocompromised patients.
• Cardiac monitoring required at initiation due to bradyarrhythmias observed in some patients.

These factors influence prescribing practices and patient adherence, affecting sales growth potential.

How does competitive positioning impact the investment outlook?

Competitors include Tecfidera, Aubagio (teriflunomide), and newer agents like Zeposia (ozanimod) and Mayzent (siponimod). PONVORY holds advantages with an oral route and convenience. However, its market penetration is challenged by:

• Established efficacy of competitors.
• Safety alerts, notably PML and cardiac risks.
• Patent expiration risks, although patent protections extend into 2030s.

What are future growth drivers and risks?

Growth drivers:

• Expansion into emerging markets facing rising MS prevalence.
• Potential label expansions for secondary progressive MS.
• Increased prescriber acceptance due to oral formulation.

Risks:

• Competitive erosion from newer S1P receptor drugs.
• Regulatory constraints concerning safety.
• Pricing pressures in developed markets.
• Patent cliff risks expected around 2030.

What is the financial forecast for PONVORY?

Analysts project PONVORY sales could reach $2 billion annually by 2025 if market share increases to 10-12%. Growth hinges on:

• Broader indication approvals.
• Increased prescription volumes.
• Competitive positioning against newer agents.

Pricing varies by market but averages approximately $60,000/year in the U.S.

Key investment considerations

• Market penetration: PONVORY remains below the market leaders but benefits from brand recognition within AbbVie's portfolio.
• Safety profile: Safety concerns temper rapid adoption but are manageable with proper monitoring.
• Patent and regulatory landscape: Patent protections afford exclusivity into the early 2030s; upcoming biosimilar threats are limited due to the nature of the molecule.
• Pipeline prospects: No significant pipeline of PONVORY derivatives reported, limiting upside from pipeline innovation.

---

Key Takeaways

• PONVORY’s steady sales growth reflects its niche as an oral MS therapy with a favorable safety profile.
• Market expansion relies on prescriber acceptance, safety management, and emerging markets.
• Competition is intensifying from newer oral agents with improved safety profiles.
• Patent protections extend through the early 2030s, providing revenue visibility.
• Future sales growth depends on market share increase and potential label extensions.

---

FAQs

1. What are the main advantages of PONVORY over injectable MS therapies?
Oral administration improves patient convenience and adherence, reducing the need for injections and potentially improving quality of life.

2. How significant are safety concerns regarding PML?
PML is rare but serious; patient screening and monitoring are mandatory, which can impact prescriber and patient acceptance.

3. When is PONVORY’s patent set to expire?
Patent protection extends into the early 2030s, though biosimilar competition is unlikely due to molecule complexity.

4. Can PONVORY be used for secondary progressive MS?
Regulatory approval is limited to relapsing forms; future label extensions could open new markets.

5. What is the predicted market share for PONVORY in the next five years?
Expected to increase to approximately 8-12%, contingent on market dynamics and competitive positioning.

---

References

[1] IQVIA. (2022). Global MS Market Overview.
[2] AbbVie. (2022). Annual Sales Reports.